Malaysia Medical Devices 2020 Market is Expected Grow to 25% of the Healthcare Expenditure

The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the Malaysia’s pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by team of industry experts.

In 2013, Malaysia's population stood at 29.9 million. The past five years have seen steady population growth, which is expected to continue in the future due to a high birth rate, low mortality rate and increased life expectancy. Government initiatives such as Entry Point Projects (EPPs), specifically EPP3, and National Key Economic Areas (NKEAs) to increase investment in the pharmaceutical industry have so far have been successful. The country's pharmaceutical market was estimated at $1.2 billion in 2008 and is projected to reach approximately $3.7 billion by 2020 at a CAGR of 9.5%. The medical device market was worth approximately $585m in 2010, but is growing and currently constitutes approximately 25% of the healthcare expenditure.

Inquire before buying this research at: .

These positive trends can primarily be attributed to -

·         Government initiatives

·         Universal healthcare coverage

Scope for this research:

The report provides information on the healthcare, regulatory, and reimbursement landscape in Malaysia, and includes -

·         An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

·         Profiles and SWOT analyses of the major players in the pharmaceutical market: Chemical Company of Malaysia Berhad, Pharmaniaga Berhad, Hovid Berhad, Apex Healthcare Berhad and Y.S.P. Southeast Asia Holding Berhad

·         Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices

·         Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure

·         An overview of the opportunities for and challenges to growth in the Malaysian healthcare market

Reasons to buy this research:

This report will enhance your decision-making capability by allowing you to -

·         Develop business strategies by understanding the trends shaping and driving Malaysia's healthcare market

·         Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future

·         Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors

·         Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

·         Identify, understand, and capitalize on the opportunities and challenges in Malaysia's healthcare market

Complete market outlook on ‘Malaysia's - Healthcare’ spread across 205 pages at .

Table of contents:

·         Overview of Pharmaceutical and Medical Device Markets

·         Market Access

·         Malaysia's Analysis of the Current Political Environment

·         Economic Indicators Malaysia's Analysis

·         Healthcare Infrastructure Malaysia's Analysis

·         Trade Associations Malaysia's Analysis

·         Opportunities and Challenges

·         List of Tables

·         List of Figures